Literature DB >> 29755010

Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report.

Bilgehan Aygen1, Ahmet Muzaffer Demir2, Mahmut Gümüş3, Oğuz Karabay4, Sabahattin Kaymakoğlu5, Aydın Şeref Köksal6, İftihar Köksal7, Necati Örmeci8, Fehmi Tabak9.   

Abstract

This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, prophylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to an emergency risk of hepatitis B reactivation. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29755010      PMCID： PMC6284666          DOI： 10.5152/tjg.2018.18263

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN： 1300-4948            Impact factor:   1.852


  43 in total

1.  Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection.

Authors:  Robin Biswas; Edward Tabor; Chu Chieh Hsia; David J Wright; Megan E Laycock; Eberhard W Fiebig; Lorraine Peddada; Richard Smith; George B Schreiber; Jay S Epstein; George J Nemo; Michael P Busch
Journal:  Transfusion       Date:  2003-06       Impact factor: 3.157

2.  Chronic hepatitis B: update 2009.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

3.  Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.

Authors:  Cindy M Weinbaum; Ian Williams; Eric E Mast; Susan A Wang; Lyn Finelli; Annemarie Wasley; Stephanie M Neitzel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2008-09-19

4.  Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.

Authors:  W Yeo; P K Chan; S Zhong; W M Ho; J L Steinberg; J S Tam; P Hui; N W Leung; B Zee; P J Johnson
Journal:  J Med Virol       Date:  2000-11       Impact factor: 2.327

5.  High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation.

Authors:  George K K Lau; Yu-hung Leung; Daniel Y T Fong; Wing-yan Au; Yok-lam Kwong; Albert Lie; Ji-lin Hou; Yu-mei Wen; Amin Nanj; Raymond Liang
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

6.  Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression.

Authors:  Tara N Palmore; Neeral L Shah; Rohit Loomba; Brian B Borg; Uri Lopatin; Jordan J Feld; Farooq Khokhar; Glen Lutchman; David E Kleiner; Neal S Young; Richard Childs; A John Barrett; T Jake Liang; Jay H Hoofnagle; Theo Heller
Journal:  Clin Gastroenterol Hepatol       Date:  2009-07-01       Impact factor: 11.382

7.  Reactivation of hepatitis B.

Authors:  Jay H Hoofnagle
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

8.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Authors:  A S Lok; R H Liang; E K Chiu; K L Wong; T K Chan; D Todd
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

9.  A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.

Authors:  Chiun Hsu; Chao A Hsiung; Ih-Jen Su; Wei-Shou Hwang; Ming-Chung Wang; Sheng-Fung Lin; Tseng-Hsi Lin; Hui-Hua Hsiao; Ji-Hsiung Young; Ming-Chih Chang; Yu-Min Liao; Chi-Cheng Li; Hung-Bo Wu; Hwei-Fang Tien; Tsu-Yi Chao; Tsang-Wu Liu; Ann-Lii Cheng; Pei-Jer Chen
Journal:  Hepatology       Date:  2008-03       Impact factor: 17.425

10.  Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.

Authors:  W Yeo; B Zee; S Zhong; P K S Chan; W-L Wong; W M Ho; K C Lam; P J Johnson
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640
View more
  6 in total

1.  Is there any evidence implying the use of a different criterion for protective anti-HBs titer after HBV vaccination in immunosuppressed patients?

Authors:  İmran Hasanoğlu; Rahmet Güner
Journal:  Turk J Gastroenterol       Date:  2020-04       Impact factor: 1.852

2.  Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection.

Authors:  Süleyman Sayar; Kemal Kürbüz; Resul Kahraman; Oğuzhan Öztürk; Zuhal Çalışkan; Hamdi Levent Doğanay; Kamil Özdil
Journal:  Turk J Gastroenterol       Date:  2020-07       Impact factor: 1.852

Review 3.  Hepatitis B virus-related liver cirrhosis complicated with dermatomyositis: A case report.

Authors:  Juan Zhang; Xiao-Yu Wen; Run-Ping Gao
Journal:  World J Clin Cases       Date:  2019-05-26       Impact factor: 1.337

Review 4.  Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID-19 (Review).

Authors:  Liliana Baroiu; Lucreția Anghel; Alin Laurențiu Tatu; Alina Viorica Iancu; Caterina Dumitru; Ana-Cristina Leșe; Miruna Drăgănescu; Florentina Năstase; Elena Niculeț; Silvia Fotea; Aurel Nechita; Doina Carina Voinescu; Anca Ioana Stefanopol
Journal:  Exp Ther Med       Date:  2022-04-12       Impact factor: 2.751

Review 5.  Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment.

Authors:  Georgios Axiaris; Evanthia Zampeli; Spyridon Michopoulos; Giorgos Bamias
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

6.  Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia

Authors:  Gülşen İskender; Dicle İskender; Mustafa Ertek
Journal:  Turk J Haematol       Date:  2020-04-06       Impact factor: 1.831
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.